Volume 10 Supplement 1
Health-care reform and its anticipated impact on the capacity of addiction health services to implement integrated care practices
© Guerrero et al; licensee BioMed Central Ltd. 2015
Published: 20 February 2015
Little is known about how different components of the Affordable Care Act (ACA) will be implemented in publicly funded addiction health services (AHS).
To examine providers’ interpretation of their external environment and anticipation of how the ACA will affect AHS structure, organization, and capacity to deliver integrated care to an increasingly diverse population.
We relied on data collected in 2013 from a purposively selected group of 30 AHS providers in Los Angeles County, California. Semistructured interviews were conducted with managers prior to enactment of ACA. Data were transcribed, coded, and analyzed using ATLAS.ti software. We relied on an intercoder approach to identify, synthesize, and summarize main themes from interviews.
Five main themes showed that ACA design criteria were disconnected from expectations to increase access and standards of care. Providers were concerned about how public and private insurance expected to achieve workforce professionalization, while also weakening the role of current staff with recovery practice experience. Service delivery was expected to broaden, yet the managed-care model used in public health insurance coverage would reduce service intensity and have a limited impact on disparities. Providers anticipated that they would not have the capacity to implement prevention and integration of mental health and primary care, as required by the ACA. Overall, providers had not enacted changes and stressed their need for a coherent action plan to improve standards of care and reduce disparities as mandated by the ACA.
These findings provide an initial view of provider interpretations, expectations, and reactions to a new health care environment. Implications for advancing public health services and systems research are discussed.
This study was funded by the National Institute on Drug Abuse (R21DA035634-01).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.